180 Life Sciences Corp. Archives - Page 2 of 2

FridaySep 25, 2020 2:41 pm

QualityStocksNewsBreaks – 180 Life Sciences Corp. Advancing Lead Program, Plans Additional Clinical Trials

180 Life Sciences, a clinical-stage biotechnology company, is dedicated to producing solutions designed to battle inflammation when the body’s natural processes go awry. The company’s primary focus is to treat fibrosis and inflammation using anti-TNF therapy, designed to block the activity of TNF, a substance in the body that can cause inflammation and lead to immune-system diseases. The company is advancing on this front as discussed by a recent article that reads, “180 Life Sciences’ lead program is in phase 2b/3 clinical trials and expects to deliver its first results next year. Other clinical trials planned by the company are…

FridaySep 25, 2020 11:48 am

180 Life Sciences Corp. Leading Research into Novel Drug Therapies Expected to Produce First Results of Phase 2b/3 Trial in 2021

Anti-inflammatory therapeutics market to generate revenues of $191.42 billion through 2027 Novel drug therapy for Fibrosis and Anti-TNF trials being conducted by Professor Sir Marc Feldmann, who already developed one of the most commonly used anti-TNF medications, Remicade The number of conditions with chronic inflammation is expected to increase persistently over the next 30 years in the United States. 180 Life Sciences is in the process of being acquired by KBLM Merger Corp. and the acquisition is expected to finalize in Q4 2020 Clinical-stage biotechnology company 180 Life Sciences Corp. is leading the way with research into the world’s most…

MondaySep 21, 2020 1:49 pm

KBL Merger Corp. IV (NASDAQ: KBLM) (NASDAQ: KBLMR) (NASDAQ: KBLMW) Fulfilling IPO Goal Through Merger With 180 Life Sciences Corp.

KBL Merger Corp. IV is set to finalize the acquisition of 180 Life Sciences Corp. during Q4 2020 180 Life Sciences Corp. has several ongoing programs at different stages of development, with the leading candidate in Phase 2b/3, helping mitigate the risks involved with its drug development The merger with 180 Life Sciences will enable KBL Merger Corp. IV to enter a market expected to double in size by 2027 180 Life Sciences is growing its patent portfolio through several preclinical studies beginning in two additional areas of inflammatory novel drug studies KBL Merger Corp. (NASDAQ: KBLM) (KBL Merger Corp.…

WednesdaySep 16, 2020 10:28 am

180 Life Sciences Corp. Pursuing Novel Solutions to Inflammatory Illnesses as Merger Nears Completion

180 Life Sciences is a clinical-stage biotechnology company that is developing therapies to combat inflammation in patients with chronic inflammation-related illnesses The company is being acquired by special purpose acquisition corporation KBL Merger Corp. IV (NASDAQ: KBLM) (NASDAQ: KBLMR) (NASDAQ: KBLMW) and will be listed on the Nasdaq Capital Market under ticker symbol ATNF when the deal closes later this year Analysts forecast the anti-inflammatory therapeutics market will be worth $191.42 billion by 2027, growing at a CAGR of 3 percent 180 Life Sciences is completing phase 2b/3 clinical trials tackling fibrosis and inflammation-causing TNF substance aberrations The sudden and…

TuesdaySep 15, 2020 12:42 pm

QualityStocksNewsBreaks – Why 180 Life Sciences Corp. Is ‘One to Watch’

180 Life Sciences, a clinical-stage biotechnology company, is focused on the development of novel drugs that fulfill unmet needs for a variety of conditions including fibrosis, pain and inflammatory diseases. 180 Life Sciences will soon form a combined company with KBL Merger Corp. (NASDAQ: KBLM) (KBL Merger Corp. Rights NASDAQ: KBLMR) (KBL Merger Corp. Warrant NASDAQ: KBLMW), a Special Purpose Acquisition Corporation (SPAC), with the new entity to be listed under ticker symbol “ATNF” on Nasdaq Capital Market. A recent article discussing the company reads, “180 Life Sciences is leading the research into solving one of the world’s biggest drivers…

WednesdaySep 09, 2020 12:23 pm

180 Life Sciences Corp. is “One to Watch”

180 Life Sciences boasts a world-class team responsible for developing new classes of drugs targeting multiple disease states while creating significant shareholder value The company has a large and expanding patent portfolio The risks associated with the company’s drug development efforts are mitigated through the concurrent advancement of multiple programs in different stages of development 180 Life Sciences decreases costs and expedites time to market through the use of grant funding, cost-effective international trials and recruitment of hospital-based luminaries who attract teams of excellence KBL Merger Corp. (NASDAQ: KBLM) (KBL Merger Corp. Rights NASDAQ: KBLMR) (KBL Merger Corp. Warrant NASDAQ:…

Site Search

Company Search

Tag: 180 Life Sciences Corp.

QualityStocksNewsBreaks – 180 Life Sciences Corp. Advancing Lead Program, Plans Additional Clinical Trials

180 Life Sciences Corp. Leading Research into Novel Drug Therapies Expected to Produce First Results of Phase 2b/3 Trial in 2021

KBL Merger Corp. IV (NASDAQ: KBLM) (NASDAQ: KBLMR) (NASDAQ: KBLMW) Fulfilling IPO Goal Through Merger With 180 Life Sciences Corp.

180 Life Sciences Corp. Pursuing Novel Solutions to Inflammatory Illnesses as Merger Nears Completion

QualityStocksNewsBreaks – Why 180 Life Sciences Corp. Is ‘One to Watch’

180 Life Sciences Corp. is “One to Watch”

Market Basics

Newsletter Publishers

Public Companies